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Abstract 
 
Purpose of review:  
Until recently, conflicting data led to discrepancies in guideline recommendation on ‘when 
to start’ antiretroviral therapy in asymptomatic HIV infection. This review focuses on 
evidence underpinning guidelines over the past decade and recent RCT data in this area 
which definitively informed the debate.  
 
 
Recent findings:  
In 2015, the landmark START trial demonstrated clear clinical benefit in terms of a reduction 
in serious AIDS and non AIDS related events and death from any cause in HIV-positive 
individuals randomised to start ART with a CD4 count >500 cells/μL compared to deferring 
starting until CD4 count declined to 350 cells/μL. Further RCT data was also available from 
the Temprano trial in Côte D'Ivoire which also demonstrated a reduced risk of death 
associated with earlier ART initiation. 
 
 
Summary:  
Following the results of the START trial, guidelines that had previously set CD4 thresholds for 
treatment initiation were universally changed. This is likely to reduce mortality in people 
living with HIV who are diagnosed early and have immediate access to ART. However unless 
HIV testing rates and ART coverage are increased globally, raising the threshold for initiation 
of ART in clinical guidelines may be of limited benefit in reducing mortality in HIV. 
  
Introduction 
Until 2015, conflicting data mainly from observation studies led to discrepancies in guideline 
panel recommendations on ‘when to start’ antiretroviral therapy (ART) in asymptomatic HIV 
infection. This review focuses on the evidence underpinning guidelines over the past 
decade, recent RCT data which definitively informed the debate on when to start ART as well 
as other factors such as testing rates that may impact on affected survival of people living 
with HIV infection despite guideline recommendations on treatment thresholds.  
 
History of guideline development and when to start 
Untreated HIV-infection causes progressive CD4 depletion and an increasing risk of AIDS-
defining illnesses and death.  Although many antiretroviral drugs are associated with 
adverse events, there is now irrefutable evidence that at lower CD4 counts the benefits of 
antiretroviral therapy (ART) far outweigh any risks of treatment. Until recently, however, 
there was no clear consensus regarding precisely when (i.e. at what CD4 count) an HIV-
positive person should start ART. This lack of consensus was reflected in considerable 
variation between ‘when to start’ guidelines.  For example, the European AIDS Clinical 
Society (EACS) guidelines from as recently as 2012 recommended commencement of ART in 
individuals who had a CD4 count below 350 cells/μL, consideration of ART in asymptomatic 
individuals who had a CD4 count between 350-500 cells/μL and deferral of ART among 
individuals with CD4 counts >500 cells/μL [1]. Similar recommendations (at similar CD4 
thresholds) were made in the UK 2012 British HIV Association (BHIVA) guidelines [2].  
However from July 2012, World Health Organization (WHO) guidelines, developed primarily 
for resource-poor settings, recommended starting ART at a threshold of 500 CD4 cells/μL [3] 
and subsequently the 2014 EACS guidelines recommended considering starting ART in 
individuals with a CD4 count >500 cells/μL [4]. 
In the US however, the Department of Health and Human Services (DHHS) [5], and the 
International AIDS Society-USA (IAS-USA) [6] guidelines were both changed in 2012 to 
recommend that ART be initiated in all people with HIV, regardless of CD4 count.  This 
change in US guidelines to start ART at higher CD4 counts was based on evidence from 
observational studies in particular the North American AIDS Cohort Collaboration on 
Research and Design (NA-ACCCORD) research cohort [7] and trials without a clinical 
endpoint such as the set point study  [8]; these changes in recommendations were, at the 
time, controversial [9] as observational studies could not fully adjust for the potentially 
strong effects of all potential confounders. In light of the changes to the US guidelines, the 
UK BHIVA guidelines group reviewed the available evidence in 2013 and issued updated 
guidelines with the unchanged recommendation to start ART at a CD4 count of 350 cells/μL 
stating that this was based on the lack of data available from any randomised clinical trial 
with a suitable comparator arm that demonstrated that the individual benefits of ART 
outweighed any risks. [10]  
However even within those guidelines, such as those from EACS and BHIVA, which carried 
general recommendations not to start ART in all people with HIV at higher CD4 counts, 
commencement of ART was recommended for certain groups of people with HIV including: 
those with hepatitis B and hepatitis C virus confections, those with any AIDs defining 
condition, pregnant women, patients needing immunosuppressive treatments for cancer, 
and also those with some HIV-related conditions including neurocognitive disorders, 
thrombocytopenia and HIV-associated nephropathy [2,4] 
 
Treatment as Prevention 
The potential individual clinical benefit of earlier treatment was not the only factor 
influencing the debate regarding when people diagnosed with HIV should start ART. There 
was increasing recognition that early ART also had the potential to reduce onward 
transmission of HIV.  A number of observational studies had reported that people on ART 
with a suppressed viral load have markedly reduced infectiousness [11-13]. The first 
randomised evidence however came from the HIV Prevention Trials Network (HPTN) 052 
Trial, which prospectively evaluated the effect of ART on prevention of HIV transmission to 
HIV negative heterosexual partners [14]. This study reported a 96% reduction in 
transmissions of HIV in serodifferent couples with a CD4 count of 350-550 cells/μL at entry 
who were assigned to the early ART arm compared to those in whom ART was deferred to a 
CD4 count <250 cells/μL; this protective effect persisted [15]. The results of this landmark 
trial dramatically increased interest in the use of ART for prevention and European, WHO 
and US treatment guidelines were revised to recommend that clinicians provide an 
explanation to all HIV-positive individuals of the beneficial effect of ART on infectiousness, 
with the offer of ART to anyone who wants to take it to reduce transmission risk, regardless 
of CD4 count [4, 16,17]. Data on transmission risk through anal sex in the context of 
suppressive ART was provided through the PARTNER observational study.  This study 
followed serodifferent heterosexual and men having sex with men (MSM) couples in which 
the HIV-positive partner was using suppressive ART and who reported condomless sex.  Over 
a median follow-up of 1238 total couple-years-follow-up, the investigators found no 
documented cases of within-couple HIV transmission [18, JAMA in press]. 
 
Evidence informing the ‘when to start’ question 
Initial evidence informing the ‘when to start’ question and the potential mortality benefits of 
ART initiation at higher CD4 counts came from observational cohort data from North 
American and European cohort collaborations. However these collaborations reported 
conflicting results. The NA-ACCCORD research group evaluated data from 22 research 
cohorts in the US and Canada to simulate a randomized strategy trial of early versus 
deferred therapy comparing all-cause mortality among those who started ART with a CD4 
count >500 cells/μL and those who started within 1.5 years of their CD4 count falling to <500 
cells/μL [7]. Deferral of therapy until the CD4 count fell <500 cells/μL was associated with a 
statistically significant 60% increase in the hazard of death, although there were inevitable 
concerns about confounding as with all cohort data. However these data strongly influenced 
the US guidelines in 2012 to recommend starting ART at any CD4 count.  
The findings of the European led groups were perhaps not surprisingly different given the 
different study designs and different populations studied. The Antiretroviral Therapy Cohort 
Collaboration (ART-CC) analysis of 18 cohorts which accounted for lead time and unseen 
AIDS and death events prior to treatment initiation, reported that at progressively lower 
CD4 thresholds for starting ART, the risk of AIDS or death increased and that delaying ART to 
<350 (but not <375) cells/μL was associated with an increased risk of AIDS or death [19]. The 
HIV-CAUSAL collaboration used prospective observational data and dynamic marginal 
structural models to compare ART initiation strategies for CD4 thresholds between 200 and 
500 cells/μL, and reported that whilst initiation of ART at a CD4 threshold of 500 cells/μL 
increased AIDS-free survival, mortality did not vary substantially if ART was initiated 
between 300 and 500 cells/μL [20] 
A more recent analysis examined the impact of CD4 count at ART initiation on longer-term 
mortality after starting ART using ART-CC cohort data [21].  The analysis found a clear 
increase in cumulative 15 year mortality with ART initiation at decreasing CD4 counts, from 
7.1% with initiation at >500 cells/μL increasing to 10.6% with initiation at <50 cells/μL. The 
inverse association of CD4 count at ART initiation with mortality was strongest during the 
first year after ART initiation, but subsequently reduced over the next 4 years so that from 5 
years after initiation of ART even those who had initiated with very low baseline CD4 values 
had similar mortality risk to those who initiated ART at intermediate or high CD4 counts.  
The evidence for potential individual clinical benefit of earlier treatment came from three 
trials which randomized people with a CD4 cell count >350 cells/μL to start ART or to defer 
treatment.  The first of the trials which reported evidence to inform the ‘when to start’ 
debate was the HPTN 052 study which randomized individuals to start ART when their CD4 
count was between 350-500 cells/μL (early therapy) or when their CD4 counts had fallen 
below 250 cells/μL or when symptoms developed (delayed therapy). A relative reduction of 
41% was reported in the number of HIV-related clinical events in the early ART group and 
this was largely due to reduced incidence of extra-pulmonary tuberculosis in this group. 
However those in the delayed comparator arm started treatment at a significantly lower 
CD4 cell counts than recommended in any guidelines since 2008. [14,22]  
 
The second trial, the ANRS 12136 Temprano trial [23], recruited 1600 participants in Côte 
D'Ivoire and presented results in early 2015. This study randomized HIV-positive people with 
a CD4 cell count <800 cells/μL to immediate ART or to receipt of ART in accordance with 
WHO criteria for initiation of therapy. However the WHO criteria changed several times over 
the course of the trial from <200 cells/μL (Mar to Dec 2009) to <350 cells/μL (Dec 2009 to Jul 
2012) and then to <500 cells/μL (Jul 2012 to Dec 2014). Again, while the trial results 
demonstrated a reduced risk of death associated with earlier ART initiation this was against 
a comparator of <200 cells/μL for much of the follow-up time which was a much lower level 
than would be considered clinically acceptable in published guidelines. 
 
The pivotal evidence informing when to initiate ART in people with asymptomatic HIV 
infection came from the Strategic Timing of Antiretroviral Treatment (START) trial [24].  In 
START, HIV-positive individuals with a CD4 count >500 cells/μL were randomized to 
immediate ART initiation or deferral until their CD4 count declined to 350 cells/μL.  In May 
2015 the trial Data Safety and Monitoring Board (DSMB) recommended on the basis of an 
interim analysis that all participants be offered ART as immediate initiation of therapy was 
associated with clear clinical benefit in terms of a reduction in the incidence of serious AIDS-
related, serious non-AIDS-related events and death from any cause compared to deferring 
ART until the CD4 count declined to <350 cells/μL.  A total of 86 events occurred among 
those randomised to the deferred ART arm, whereas 41 events occurred among those 
starting ART immediately, representing a 57% reduction among those treated early; notably, 
this overall reduction included a reduction in tuberculosis, lymphoma and Kaposi’s Sarcoma.  
In both groups, most events occurred when CD4 counts were higher than 500 cells/μL. 
 
Following the results of the START trial, guidelines that had previously set CD4 thresholds for 
treatment initiation were universally changed, with the WHO guidelines in September 2015 
recommending that ART should be initiated in all adults living with HIV at any CD4 cell count 
[25] (though with priority given to treating people with severe or advanced HIV clinical 
disease or a CD4 count ≤350 cells/μL) and the BHIVA and EACS guidelines following suit 
shortly afterwards [26,27].   
 
 
Impact of other factors on survival of people living with HIV 
With the evidence now clear for the mortality benefits of ART initiation at higher CD4 
counts, the reality is that ART roll-out to all those in need of HIV treatment remains far from 
complete, particularly in countries with a high HIV burden. Only 41% of all people with HIV 
were on ART by March 2015 [25] and the median CD4 count at ART initiation, although 
increasing, remains lower than a threshold of 350 cells/μL in both low and high-income 
settings. [28,29] 
 
The reasons for this are multiple and complex, but HIV testing rates remain too low. It is 
widely acknowledged that the biggest obstacle to meeting the UNAIDS 90-90-90 global 
targets by 2020 (90% knowing their HIV status, 90% with diagnosed HIV infection on ART 
and 90% on ART achieving virological suppression) remains the high proportion of people 
living with HIV who remain undiagnosed. Globally, 47% of people living with HIV remain 
undiagnosed and often present only when their CD4 cell counts have fallen to a level where 
immune systems are badly damaged and clinical complications have arisen [30]. In a study of 
late presenters in Europe, those who presented with a CD4 cell count of <350 cells/µL or an 
AIDS diagnosis within 6 months of HIV diagnosis had over a 10-fold increased risk of dying 
within a year of diagnosis, compared to those diagnosed earlier [31] 
 
Testing rates remain less than recommended even among groups at risk in resource-rich 
settings with 25% of MSM in the UK never having tested for HIV [32]. In addition very few 
MSM meet the recommended frequency of testing, with only 55% testing every year and 
only 27% of those considered at high risk (defined as having a new condomless sex partner 
in the last 3 months or a diagnosis of an STI) testing every 3 months [33]. Testing frequency 
in people of Black African ethnicity in the UK who are at increased risk of presenting late 
with HIV is also low with an estimated 39% to 57% having never been tested. [34] 
 
In addition, the success of ART is highly dependent on readiness to start and motivation to 
adhere to treatment. Trial participants are a selected group who necessarily must agree in 
principle to randomisation to early treatment, and may well have a preference for early ART, 
and/or a high motivation to adhere to ART.  The prospect of what may be perceived as a 
slight health gain set against the potential negative impact on quality-of-life of long-term 
ART may reduce the incentive of some people to start ART at high CD4 counts and individual 
preferences and concerns need to be taken into account  [35]. 
 
Summary  
The clinical benefits of starting ART at higher CD4 thresholds on mortality have been clearly 
demonstrated in a clinical trial setting, and there may in fact be even greater long-term 
survival benefits of earlier ART which only become apparent after many years of treatment. 
However, unless HIV testing rates and ART coverage are increased globally with diagnosis 
and initiation of ART early in the clinical course of HIV infection before the immune system is 
damaged, raising the threshold for initiation of ART in clinical guidelines may be of limited 
benefit in reducing mortality in HIV.  
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